KBC Securities - ADYEN (ADYEN NA) Morning Note: ADYEN NA

Report

KBC Securities

Thomas Couvreur

Morning Note: ADYEN NA

Adyen: Prudence warranted from sector trends headwinds

13/12/2021 1 EN

Underlying

ADYEN

See profile

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Couvreur

Other Reports on these Companies

KBC Securities

ADYEN: Prudence warranted from sector trends headwinds ADYEN NA

Today we published a note on Adyen, highlighting some of the sector trends we see at enterprise-level merchants and peers. We appreciate Adyen’s strong positioning in a market that will continue to see activity shift away from incumbent players, supporting Adyen’s high growth. Several market trends that we expect to become more prevalent going forwards, counter some of the key selling points of the Adyen platform. With this longer-term view, we believe many of the TPs on the street are too bullish. We reiterate our Reduce rating, though increase our TP to €2,250 based on increased eBay take-up...

December 13, 2021 December 13, 2021 1 EN

Bryan Garnier

ADYEN (BUY, TP EUR2,900) | eBay acquires 1.25% of Adyen by exercising the first tranche of its warrants

December 3, 2021 December 3, 2021 3 EN

Amoéba Exemption from obligation to destroy trial crops in France

The French regulator ANSES has granted an exemption for Amoéba's biocontrol product Axpera, allowing crop trials without the usual requirement to destroy the harvest. This exemption, which applies to both open-field and greenhouse crops affected by various diseases, supports ongoing evaluations and follows recent regulatory milestones in France and the EU. While no material commercial sales are expected yet in 2025, the move is seen as another strong endorsement of Amoéba's innovative technology and a step closer to full market approval, reinforcing our confidence in the company's future poten...

9h / 5m 9h / 5m 1 EN

Livio Luyten ... (+2)

Livio Luyten
Wim Lewi

Morning Notes : GIMBb BB, WDP BB

: GIMBb BB, WDP BB

11h / 47m 11h / 47m 1 EN

Jacob Mekhael

Jacob Mekhael

ADA amylin monotherapy highlights Zealand, Novo, Lilly

The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with headaches and depressive mood side effects, and Novo's CagriSema phase 3 full data publication, which in ...

June 24, 2025 June 24, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Note: ADYEN NA

We are a financial services provider for several types of professional clients, each with distinct needs.

ADYEN: Prudence warranted from sector trends headwinds ADYEN NA

ADYEN (BUY, TP EUR2,900) | eBay acquires 1.25% of Adyen by exercising the first tranche of its warrants

Amoéba Exemption from obligation to destroy trial crops in France

Morning Notes : GIMBb BB, WDP BB

ADA amylin monotherapy highlights Zealand, Novo, Lilly

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe